

#### 115TH CONGRESS 1ST SESSION

# H. R. 993

To reduce opioid misuse and abuse.

### IN THE HOUSE OF REPRESENTATIVES

February 9, 2017

Mr. Foster (for himself, Mr. Swalwell of California, and Mr. Sean Pat-RICK Maloney of New York) introduced the following bill; which was referred to the Committee on Energy and Commerce

## A BILL

To reduce opioid misuse and abuse.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Opioid Abuse Preven-
- 5 tion and Treatment Act of 2017".
- 6 SEC. 2. PILOT PROJECT.
- 7 (a) In General.—The Secretary of Health and
- 8 Human Services (referred to in this Act as the "Sec-
- 9 retary") shall award grants to one or more States to carry
- 10 out a 1-year pilot project to develop a standardized peer
- 11 review process and methodology to review and evaluate

- 1 prescribing and pharmacy dispensing patterns, through a
- 2 review of prescription drug monitoring programs (referred
- 3 to in this section as "PDMP") in the States receiving such
- 4 grants.
- 5 (b) Methodology.—The recipients of a grant under
- 6 this section shall develop a systematic, standardized meth-
- 7 odology to identify and investigate questionable or inap-
- 8 propriate prescribing and dispensing patterns of sub-
- 9 stances on schedule II or III under section 202 of the Con-
- 10 trolled Substances Act (21 U.S.C. 812). Such peer review
- 11 methodology and prescribing and dispensing patterns shall
- 12 be shared with the appropriate State regulators and health
- 13 profession boards.
- 14 (c) Requirements.—A State receiving a grant
- 15 under this section—
- 16 (1) with respect to controlled substances for
- which a prescriber is required to be registered with
- by the Drug Enforcement Administration in order to
- 19 prescribe such controlled substances, shall make the
- information with respect to such controlled sub-
- stances from the PDMP available to State regu-
- 22 lators and licensing boards; and
- 23 (2) with respect to any other controlled sub-
- stances, may make the information with respect to

1	such controlled substances from the PDMP available
2	to State regulators and licensing boards.
3	(d) Subgrantees.—A quality improvement organi-
4	zation with which the Secretary has entered into a con-
5	tract under part B of title XI of the Social Security Act
6	(42 U.S.C. 1320c et seq.) may serve as the subgrantee
7	under this subsection to develop peer review processes as
8	described in subsection (a).
9	SEC. 3. PRESCRIPTION DRUG, HEROIN, AND OTHER CON-
10	TROLLED SUBSTANCE ABUSE PREVENTION.
11	Part P of title III of the Public Health Service Act
12	(42 U.S.C. 280g) is amended by adding at the end the
13	following:
14	"SEC. 399V-7. PRESCRIPTION DRUG, HEROIN, AND OTHER
14 15	"SEC. 399V-7. PRESCRIPTION DRUG, HEROIN, AND OTHER CONTROLLED SUBSTANCE ABUSE PREVEN-
15	CONTROLLED SUBSTANCE ABUSE PREVEN
15 16	CONTROLLED SUBSTANCE ABUSE PREVENTION.
15 16 17	CONTROLLED SUBSTANCE ABUSE PREVEN- TION.  "(a) Training Grants.—
15 16 17 18	CONTROLLED SUBSTANCE ABUSE PREVEN- TION.  "(a) Training Grants.—  "(1) In general.—The Secretary shall award
15 16 17 18	CONTROLLED SUBSTANCE ABUSE PREVEN- TION.  "(a) Training Grants.—  "(1) In general.—The Secretary shall award 5-year grants to eligible entities to facilitate training
115 116 117 118 119 220	TION.  "(a) Training Grants.—  "(1) In General.—The Secretary shall award 5-year grants to eligible entities to facilitate training in order to increase the capacity of health care pro-
15 16 17 18 19 20 21	TION.  "(a) Training Grants.—  "(1) In General.—The Secretary shall award 5-year grants to eligible entities to facilitate training in order to increase the capacity of health care providers to conduct patient screening, brief interven-

stances. The grant program under this section may

25

1	be coordinated with the Screening Brief Intervention
2	and Referral to Treatment grant program of the
3	Substance Abuse and Mental Health Services Ad-
4	ministration, or other appropriate programs.
5	"(2) Eligible entities.—In this subsection,
6	the term 'eligible entity' includes—
7	"(A) States;
8	"(B) physician organizations;
9	"(C) continuing education entities, such as
10	health profession boards or health accrediting
11	bodies;
12	"(D) peer recovery organizations; and
13	"(E) other appropriate health or profes-
14	sional education organizations or institutions.
15	"(b) Expansion of Prescribing Authority.—
16	The Secretary, acting through the Administrator of the
17	Health Resources and Services Administration, shall
18	award grants to States for the purpose of evaluating the
19	prospect of the health professions board of such States
20	reviewing and expanding prescribing authorities of pro-
21	viders, such as advance practice nurses and physician's as-
22	sistants, with respect to prescribing drugs for the treat-
23	ment of the abuse of prescription drugs, heroin, or other
24	controlled substances.".

### 1 SEC. 4. PRESCRIPTION DRUG ABUSE TRAINING AND

- 2 SCREENING PROGRAMS.
- 3 (a) Continuing Education Grants.—The Sec-
- 4 retary shall award grants to States to develop continuing
- 5 education criteria and review processes that allow State
- 6 health profession boards or State agencies to certify ap-
- 7 propriate education and training for informed and safe
- 8 prescribing of opioids and other drugs listed on schedule
- 9 II or III under section 202 of the Controlled Substances
- 10 Act (21 U.S.C. 812).
- 11 (b) Screening Program.—The Attorney General
- 12 shall request that a practitioner registered under section
- 13 303(f) of the Controlled Substances Act (21 U.S.C.
- 14 823(f)) conduct patient screening for potential drug mis-
- 15 use or abuse before prescribing a drug listed on schedule
- 16 II or III under section 202 of the Controlled Substances
- 17 Act (21 U.S.C. 812), according to standards established
- 18 by the applicable State licensing body.
- 19 SEC. 5. FDA REVIEW OF NALOXONE.
- The Secretary, acting through the Commissioner of
- 21 Food and Drugs, shall conduct a review of naloxone to
- 22 consider whether naloxone should cease to be subject to
- 23 section 503(b) of the Federal Food, Drug, and Cosmetic
- 24 Act (21 U.S.C. 353(b)) and be available as an over-the-
- 25 counter drug, in order to increase access to such drug.

### 1 SEC. 6. PRESCRIPTION OPIATE DISPOSAL.

2	The Secretary shall convene or coordinate with an ex-
3	isting entity an interagency working group—
4	(1) to encourage States and local governments
5	to increase opportunities for disposal of opiates, such
6	as frequent "take-back programs" and fixed medi-
7	cine disposal sites at law enforcement public build-
8	ings; and
9	(2) to reduce opportunities for abuse of opiates,
10	such as establishing opioid dispensing limits at hos-
11	pital emergency departments.
12	SEC. 7. GAO REPORT.
	SEC. 7. GAO REPORT.  The Comptroller General of the United States shall—
12	
12 13	The Comptroller General of the United States shall—
12 13 14	The Comptroller General of the United States shall— (1) review opioid abuse programs, heroin abuse
12 13 14 15	The Comptroller General of the United States shall—  (1) review opioid abuse programs, heroin abuse programs, and policies in Federal agencies and best
12 13 14 15 16	The Comptroller General of the United States shall—  (1) review opioid abuse programs, heroin abuse programs, and policies in Federal agencies and best practices with respect to opioid and heroin abuse
12 13 14 15 16 17	The Comptroller General of the United States shall—  (1) review opioid abuse programs, heroin abuse programs, and policies in Federal agencies and best practices with respect to opioid and heroin abuse and overdose programs of the States; and
12 13 14 15 16 17	The Comptroller General of the United States shall—  (1) review opioid abuse programs, heroin abuse programs, and policies in Federal agencies and best practices with respect to opioid and heroin abuse and overdose programs of the States; and  (2) not later than 18 months after the date of